ZELLUNA
Research ZELLUNA (ZLNA.OL) on Bullrun: market cap NOK 647.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZLNA.OL
- ExchangeXOSL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 647.97M
- Financial periodQ2 2026
- RevenueNOK 0
- Net income-NOK 19.69M
- Free cash flow-NOK 20.05M
Valuation Snapshot
latest market cap is NOK 647.97M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-06 | NOK 647.97M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 NOK.
About ZELLUNA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ZELLUNA's market cap?
ZELLUNA's market capitalization is NOK 647.97M.
What does ZELLUNA do?
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.